BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shin HG, Yang HR, Yoon A, Lee S. Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. Int J Mol Sci 2022;23:5686. [PMID: 35628495 DOI: 10.3390/ijms23105686] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Ghaedrahmati F, Esmaeil N, Abbaspour M. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. Cancer Commun (Lond) 2022. [PMID: 36585761 DOI: 10.1002/cac2.12394] [Reference Citation Analysis]
2 Nguyen A, Kumar S, Kulkarni AA. Nanotheranostic Strategies for Cancer Immunotherapy. Small Methods 2022;6:e2200718. [PMID: 36382571 DOI: 10.1002/smtd.202200718] [Reference Citation Analysis]
3 Arvedson T, Bailis JM, Urbig T, Stevens JL. Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies. Curr Opin Biotechnol 2022;78:102799. [PMID: 36179408 DOI: 10.1016/j.copbio.2022.102799] [Reference Citation Analysis]
4 Liguori L, Polcaro G, Nigro A, Conti V, Sellitto C, Perri F, Ottaiano A, Cascella M, Zeppa P, Caputo A, Pepe S, Sabbatino F. Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors. Pharmaceutics 2022;14. [PMID: 36432631 DOI: 10.3390/pharmaceutics14112442] [Reference Citation Analysis]
5 Zhan M, Guo Y, Shen M, Shi X. Nanomaterial‐Boosted Tumor Immunotherapy Through Natural Killer Cells. Advanced NanoBiomed Research 2022. [DOI: 10.1002/anbr.202200096] [Reference Citation Analysis]
6 Passariello M, Yoshioka A, Takahashi K, Hashimoto S, Inoue T, Nakamura K, De Lorenzo C. Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo. J Exp Clin Cancer Res 2022;41:269. [DOI: 10.1186/s13046-022-02474-3] [Reference Citation Analysis]
7 Komatsu SI, Kayukawa Y, Miyazaki Y, Kaneko A, Ikegami H, Ishiguro T, Nakamura M, Frings W, Ono N, Sakata K, Fujii T, Kishishita S, Kitazawa T, Endo M, Sano Y. Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial. Sci Rep 2022;12:12312. [PMID: 35853994 DOI: 10.1038/s41598-022-16564-x] [Reference Citation Analysis]